Paratek Pharmaceuticals

Paratek Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for diseases or other public health threats for civilian, government and military use. The company's U.S. Food and Drug Administration approved commercial product, NUZYRA? (omadacycline), is a once-daily oral and intravenous antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens. SEYSARA? (sarecycline) is being marketed by Almirall, LLC in the U.S. as a new once-daily oral therapy for the treatment of moderate to severe acne vulgaris.
  • TickerPRTK
  • ISINUS6993743029
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
 PRESS RELEASE
PRTK Paratek Pharmac... (Health Care)

Paratek Pharmaceuticals Announces Initiation of Phase 2b Study in Nont...

Paratek Pharmaceuticals Announces Initiation of Phase 2b Study in Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium abscessus Complex (MABc) with NUZYRA® (omadacycline) -- U.S.-Based Sites Ready to Begin Enrolling Patients, Placebo-Controlled Study Evaluating NUZYRA Efficacy at 12 Weeks of Treatment -- Potential $1.0 Billion Addressable Market Opportunity in the U.S. Based on Company Estimates -- Paratek Hosting Investor Webinar with Corporate Updates and Key Opinion Leader and Patient Advocate Presentations on NTM abscessus today, June 16, 2021 at 10:00am ET -...

 PRESS RELEASE
PRTK Paratek Pharmac... (Health Care)

Paratek Appoints Minnie Baylor-Henry to Company’s Board of Directors

Paratek Appoints Minnie Baylor-Henry to Company’s Board of Directors BOSTON, June 14, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced the appointment of Minnie Baylor-Henry, J.D., a recognized leader in the area of food and drug laws and regulations, to the company’s Board of Directors. “We’re delighted to welcome Minnie...

 PRESS RELEASE
PRTK Paratek Pharmac... (Health Care)

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(...

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) BOSTON, June 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that on May 28, 2021, the Company granted stock options to six new employees of the Company. These awards were granted pursuant to the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, a...

 PRESS RELEASE
PRTK Paratek Pharmac... (Health Care)

Paratek Pharmaceuticals Announces FDA Approval of NUZYRA® (omadacyclin...

Paratek Pharmaceuticals Announces FDA Approval of NUZYRA® (omadacycline) Oral Only Dosing Regimen for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) - Oral-only dosing for the Treatment of CABP Expands the Commercial Opportunity for Primary Care Promotion - Primary Care Market Opportunity for CABP Estimated at Approximately $1.5 Billion BOSTON, June 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening dis...

 PRESS RELEASE
PRTK Paratek Pharmac... (Health Care)

Paratek Pharmaceuticals Announces Initiation of Phase 2b Study in Nont...

Paratek Pharmaceuticals Announces Initiation of Phase 2b Study in Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium abscessus Complex (MABc) with NUZYRA® (omadacycline) -- U.S.-Based Sites Ready to Begin Enrolling Patients, Placebo-Controlled Study Evaluating NUZYRA Efficacy at 12 Weeks of Treatment -- Potential $1.0 Billion Addressable Market Opportunity in the U.S. Based on Company Estimates -- Paratek Hosting Investor Webinar with Corporate Updates and Key Opinion Leader and Patient Advocate Presentations on NTM abscessus today, June 16, 2021 at 10:00am ET -...

 PRESS RELEASE
PRTK Paratek Pharmac... (Health Care)

Paratek Appoints Minnie Baylor-Henry to Company’s Board of Directors

Paratek Appoints Minnie Baylor-Henry to Company’s Board of Directors BOSTON, June 14, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced the appointment of Minnie Baylor-Henry, J.D., a recognized leader in the area of food and drug laws and regulations, to the company’s Board of Directors. “We’re delighted to welcome Minnie...

 PRESS RELEASE
PRTK Paratek Pharmac... (Health Care)

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(...

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) BOSTON, June 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that on May 28, 2021, the Company granted stock options to six new employees of the Company. These awards were granted pursuant to the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, a...

 PRESS RELEASE
PRTK Paratek Pharmac... (Health Care)

Paratek Pharmaceuticals Announces FDA Approval of NUZYRA® (omadacyclin...

Paratek Pharmaceuticals Announces FDA Approval of NUZYRA® (omadacycline) Oral Only Dosing Regimen for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) - Oral-only dosing for the Treatment of CABP Expands the Commercial Opportunity for Primary Care Promotion - Primary Care Market Opportunity for CABP Estimated at Approximately $1.5 Billion BOSTON, June 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening dis...

 PRESS RELEASE
PRTK Paratek Pharmac... (Health Care)

Paratek Pharmaceuticals Announces Initiation of Phase 2b Study in Nont...

Paratek Pharmaceuticals Announces Initiation of Phase 2b Study in Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium abscessus Complex (MABc) with NUZYRA® (omadacycline) -- U.S.-Based Sites Ready to Begin Enrolling Patients, Placebo-Controlled Study Evaluating NUZYRA Efficacy at 12 Weeks of Treatment -- Potential $1.0 Billion Addressable Market Opportunity in the U.S. Based on Company Estimates -- Paratek Hosting Investor Webinar with Corporate Updates and Key Opinion Leader and Patient Advocate Presentations on NTM abscessus today, June 16, 2021 at 10:00am ET -...

 PRESS RELEASE
PRTK Paratek Pharmac... (Health Care)

Paratek Appoints Minnie Baylor-Henry to Company’s Board of Directors

Paratek Appoints Minnie Baylor-Henry to Company’s Board of Directors BOSTON, June 14, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced the appointment of Minnie Baylor-Henry, J.D., a recognized leader in the area of food and drug laws and regulations, to the company’s Board of Directors. “We’re delighted to welcome Minnie...

 PRESS RELEASE
PRTK Paratek Pharmac... (Health Care)

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(...

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) BOSTON, June 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that on May 28, 2021, the Company granted stock options to six new employees of the Company. These awards were granted pursuant to the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, a...

 PRESS RELEASE
PRTK Paratek Pharmac... (Health Care)

Paratek Pharmaceuticals Announces FDA Approval of NUZYRA® (omadacyclin...

Paratek Pharmaceuticals Announces FDA Approval of NUZYRA® (omadacycline) Oral Only Dosing Regimen for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) - Oral-only dosing for the Treatment of CABP Expands the Commercial Opportunity for Primary Care Promotion - Primary Care Market Opportunity for CABP Estimated at Approximately $1.5 Billion BOSTON, June 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening dis...

 PRESS RELEASE
PRTK Paratek Pharmac... (Health Care)

Paratek Pharmaceuticals Announces Initiation of Phase 2b Study in Nont...

Paratek Pharmaceuticals Announces Initiation of Phase 2b Study in Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium abscessus Complex (MABc) with NUZYRA® (omadacycline) -- U.S.-Based Sites Ready to Begin Enrolling Patients, Placebo-Controlled Study Evaluating NUZYRA Efficacy at 12 Weeks of Treatment -- Potential $1.0 Billion Addressable Market Opportunity in the U.S. Based on Company Estimates -- Paratek Hosting Investor Webinar with Corporate Updates and Key Opinion Leader and Patient Advocate Presentations on NTM abscessus today, June 16, 2021 at 10:00am ET -...

 PRESS RELEASE
PRTK Paratek Pharmac... (Health Care)

Paratek Appoints Minnie Baylor-Henry to Company’s Board of Directors

Paratek Appoints Minnie Baylor-Henry to Company’s Board of Directors BOSTON, June 14, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced the appointment of Minnie Baylor-Henry, J.D., a recognized leader in the area of food and drug laws and regulations, to the company’s Board of Directors. “We’re delighted to welcome Minnie...

 PRESS RELEASE
PRTK Paratek Pharmac... (Health Care)

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(...

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) BOSTON, June 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that on May 28, 2021, the Company granted stock options to six new employees of the Company. These awards were granted pursuant to the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, a...

 PRESS RELEASE
PRTK Paratek Pharmac... (Health Care)

Paratek Pharmaceuticals Announces FDA Approval of NUZYRA® (omadacyclin...

Paratek Pharmaceuticals Announces FDA Approval of NUZYRA® (omadacycline) Oral Only Dosing Regimen for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) - Oral-only dosing for the Treatment of CABP Expands the Commercial Opportunity for Primary Care Promotion - Primary Care Market Opportunity for CABP Estimated at Approximately $1.5 Billion BOSTON, June 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening dis...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch